Abstract
A recent analysis of real-world, diagnostic testing data for common biomarkers in cancer indicates that 156,000 patients miss out on appropriate treatments each year (1), due to inefficient testing practices such as slow turnaround times and inconsistent results. Consequently, these patients are taking much longer to get properly diagnosed and are not getting the best treatment available to them. The impact of these potential therapeutic options varies depending on the disease space, and ranges from improving quality of life to potentially saving lives.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
